*Result*: T cell-intrinsic PRR signaling in immunity and pathology.
Title:
T cell-intrinsic PRR signaling in immunity and pathology.
Authors:
Shi Y; Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China., Wang M; Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China., Dai B; Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China., Lu X; Department of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China., Li S; Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China.
Source:
Acta biochimica et biophysica Sinica [Acta Biochim Biophys Sin (Shanghai)] 2026 Jan 25; Vol. 58 (1), pp. 39-48. Date of Electronic Publication: 2025 Dec 19.
Publication Type:
Journal Article; Review
Language:
English
Journal Info:
Publisher: China Science Publishing & Media Ltd Country of Publication: China NLM ID: 101206716 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-7270 (Electronic) Linking ISSN: 16729145 NLM ISO Abbreviation: Acta Biochim Biophys Sin (Shanghai) Subsets: MEDLINE
Imprint Name(s):
Publication: 2022- : Shanghai : China Science Publishing & Media Ltd.
Original Publication: Shanghai : Shanghai Scientific and Technical Publishers, 2004-
Original Publication: Shanghai : Shanghai Scientific and Technical Publishers, 2004-
MeSH Terms:
References:
Front Immunol. 2023 Aug 02;14:1235590. (PMID: 37600809)
ScientificWorldJournal. 2013 Dec 29;2013:293296. (PMID: 24459426)
Nat Immunol. 2004 Jul;5(7):730-7. (PMID: 15208624)
Cancer Cell. 2022 Feb 14;40(2):136-152.e12. (PMID: 35051357)
Annu Rev Biophys. 2023 May 9;52:207-228. (PMID: 36626767)
Nat Commun. 2017 May 24;8:15402. (PMID: 28537251)
J Virol. 2013 Feb;87(3):1290-300. (PMID: 23175362)
Trends Immunol. 2020 Jan;41(1):61-76. (PMID: 31813764)
Front Immunol. 2017 Jan 03;7:662. (PMID: 28096803)
PLoS One. 2014 Nov 03;9(11):e111460. (PMID: 25365308)
Nat Commun. 2020 May 12;11(1):2361. (PMID: 32398640)
J Immunol. 2018 Jul 15;201(2):393-405. (PMID: 29884703)
Cell Death Dis. 2023 Sep 25;14(9):632. (PMID: 37749127)
J Immunol. 2012 May 15;188(10):4951-8. (PMID: 22490869)
Immunity. 2016 Jul 19;45(1):15-30. (PMID: 27438764)
Nat Rev Immunol. 2021 Sep;21(9):548-569. (PMID: 33833439)
Cell. 2010 Mar 19;140(6):805-20. (PMID: 20303872)
Nat Commun. 2024 Nov 25;15(1):10224. (PMID: 39587108)
Nat Immunol. 2022 Dec;23(12):1735-1748. (PMID: 36456734)
Trends Immunol. 2007 Jul;28(7):308-14. (PMID: 17537673)
Cell Mol Immunol. 2025 May;22(5):541-556. (PMID: 40195474)
Nat Rev Cancer. 2023 Jun;23(6):351-371. (PMID: 37081117)
Nat Immunol. 2015 Aug;16(8):859-70. (PMID: 26098997)
Target Oncol. 2012 Mar;7(1):29-54. (PMID: 22399234)
Front Oncol. 2021 Jul 26;11:711673. (PMID: 34381732)
Nat Immunol. 2015 Apr;16(4):343-53. (PMID: 25789684)
J Virol. 2013 Nov;87(21):11401-15. (PMID: 23966390)
EMBO Mol Med. 2024 Nov;16(11):3005-3025. (PMID: 39322862)
Nat Rev Immunol. 2006 Nov;6(11):823-35. (PMID: 17063184)
Annu Rev Immunol. 2014;32:461-88. (PMID: 24655297)
Immunology. 2004 Jul;112(3):369-77. (PMID: 15196204)
Nat Rev Cancer. 2022 Jul;22(7):397-413. (PMID: 35355007)
Nat Med. 2023 Sep;29(9):2278-2285. (PMID: 37592104)
Nat Immunol. 2010 May;11(5):373-84. (PMID: 20404851)
Eur J Immunol. 2010 Mar;40(3):624-7. (PMID: 20201016)
Curr Opin Virol. 2015 Jun;12:7-14. (PMID: 25644461)
Nat Immunol. 2009 Feb;10(2):203-13. (PMID: 19122653)
Immunity. 2024 Apr 9;57(4):632-648. (PMID: 38599163)
Nat Immunol. 2016 Dec;17(12):1459-1466. (PMID: 27695003)
Immunity. 2010 May 28;32(5):692-702. (PMID: 20434372)
Nat Immunol. 2021 Apr;22(4):423-433. (PMID: 33767427)
Signal Transduct Target Ther. 2025 Jul 11;10(1):216. (PMID: 40640149)
J Immunol. 2017 Mar 15;198(6):2260-2268. (PMID: 28159898)
PLoS One. 2010 Oct 18;5(10):e13418. (PMID: 20976143)
Cancer Discov. 2020 Jan;10(1):26-39. (PMID: 31852718)
Nat Rev Immunol. 2016 Jul;16(7):433-48. (PMID: 27291962)
Am J Transplant. 2011 Feb;11(2):203-14. (PMID: 21219575)
J Immunol. 2006 Nov 15;177(10):6573-8. (PMID: 17082566)
J Exp Med. 2002 Mar 4;195(5):F19-23. (PMID: 11877490)
Immunity. 2011 May 27;34(5):637-50. (PMID: 21616434)
Cells. 2020 Mar 13;9(3):. (PMID: 32183240)
Immunity. 2020 Jul 14;53(1):115-126.e5. (PMID: 32640258)
J Exp Med. 2003 Feb 17;197(4):403-11. (PMID: 12591899)
Nat Rev Immunol. 2012 Dec;12(12):813-20. (PMID: 23175229)
Cell Rep. 2021 Nov 23;37(8):110000. (PMID: 34818548)
Nature. 2014 Oct 16;514(7522):372-375. (PMID: 25119032)
Pharmaceutics. 2022 Feb 16;14(2):. (PMID: 35214155)
J Biol Chem. 1999 May 21;274(21):14560-7. (PMID: 10329646)
Front Immunol. 2021 Aug 19;12:706583. (PMID: 34489958)
J Clin Invest. 2023 May 1;133(9):. (PMID: 36927693)
Nature. 2009 Mar 26;458(7237):514-8. (PMID: 19158675)
Cell. 2006 Feb 24;124(4):783-801. (PMID: 16497588)
Nat Immunol. 2011 Feb;12(2):121-8. (PMID: 21245903)
Nature. 2021 Mar;591(7849):300-305. (PMID: 33505023)
Nat Immunol. 2005 Oct;6(10):981-8. (PMID: 16127453)
Hum Vaccin Immunother. 2024 Dec 31;20(1):2297453. (PMID: 38155525)
Cell Mol Life Sci. 2011 Jul;68(14):2357-70. (PMID: 21560072)
Front Microbiol. 2023 Jan 27;14:1033448. (PMID: 36778871)
Mol Cells. 2025 Aug;48(8):100239. (PMID: 40527410)
Signal Transduct Target Ther. 2025 Jul 18;10(1):225. (PMID: 40675966)
Scand J Immunol. 2009 Sep;70(3):245-55. (PMID: 19703014)
J Immunol. 2006 Feb 1;176(3):1348-54. (PMID: 16424161)
Clin Rheumatol. 2024 Nov;43(11):3537-3549. (PMID: 39356380)
Sci Transl Med. 2020 Jun 24;12(549):. (PMID: 32581136)
J Immunol. 2009 Jul 15;183(2):787-91. (PMID: 19570822)
Signal Transduct Target Ther. 2021 Aug 4;6(1):291. (PMID: 34344870)
Immunity. 2010 Oct 29;33(4):492-503. (PMID: 21029960)
Biomed J. 2024 Feb;47(1):100635. (PMID: 37574163)
Cell Mol Immunol. 2021 Mar;18(3):539-555. (PMID: 33462384)
Cell. 2024 Dec 26;187(26):7414-7432.e26. (PMID: 39476839)
J Immunol. 2004 May 15;172(10):6065-73. (PMID: 15128790)
Nat Commun. 2024 Feb 1;15(1):308. (PMID: 38302456)
Front Immunol. 2022 Sep 02;13:979116. (PMID: 36119037)
Front Immunol. 2018 Feb 13;9:225. (PMID: 29487599)
Nat Biomed Eng. 2018 Aug;2(8):578-588. (PMID: 31015631)
BMC Evol Biol. 2011 Dec 20;11:368. (PMID: 22185391)
Nat Med. 2017 May;23(5):556-567. (PMID: 28394331)
Cell Rep Med. 2024 May 21;5(5):101560. (PMID: 38729159)
Immunity. 2012 Aug 24;37(2):235-48. (PMID: 22841161)
Nat Rev Immunol. 2017 Mar;17(3):208-214. (PMID: 28163301)
Am J Nephrol. 2014;40(4):325-44. (PMID: 25341693)
Nat Rev Immunol. 2008 Dec;8(12):911-22. (PMID: 18989317)
Immunity. 2024 Apr 9;57(4):649-673. (PMID: 38599164)
ScientificWorldJournal. 2013 Dec 29;2013:293296. (PMID: 24459426)
Nat Immunol. 2004 Jul;5(7):730-7. (PMID: 15208624)
Cancer Cell. 2022 Feb 14;40(2):136-152.e12. (PMID: 35051357)
Annu Rev Biophys. 2023 May 9;52:207-228. (PMID: 36626767)
Nat Commun. 2017 May 24;8:15402. (PMID: 28537251)
J Virol. 2013 Feb;87(3):1290-300. (PMID: 23175362)
Trends Immunol. 2020 Jan;41(1):61-76. (PMID: 31813764)
Front Immunol. 2017 Jan 03;7:662. (PMID: 28096803)
PLoS One. 2014 Nov 03;9(11):e111460. (PMID: 25365308)
Nat Commun. 2020 May 12;11(1):2361. (PMID: 32398640)
J Immunol. 2018 Jul 15;201(2):393-405. (PMID: 29884703)
Cell Death Dis. 2023 Sep 25;14(9):632. (PMID: 37749127)
J Immunol. 2012 May 15;188(10):4951-8. (PMID: 22490869)
Immunity. 2016 Jul 19;45(1):15-30. (PMID: 27438764)
Nat Rev Immunol. 2021 Sep;21(9):548-569. (PMID: 33833439)
Cell. 2010 Mar 19;140(6):805-20. (PMID: 20303872)
Nat Commun. 2024 Nov 25;15(1):10224. (PMID: 39587108)
Nat Immunol. 2022 Dec;23(12):1735-1748. (PMID: 36456734)
Trends Immunol. 2007 Jul;28(7):308-14. (PMID: 17537673)
Cell Mol Immunol. 2025 May;22(5):541-556. (PMID: 40195474)
Nat Rev Cancer. 2023 Jun;23(6):351-371. (PMID: 37081117)
Nat Immunol. 2015 Aug;16(8):859-70. (PMID: 26098997)
Target Oncol. 2012 Mar;7(1):29-54. (PMID: 22399234)
Front Oncol. 2021 Jul 26;11:711673. (PMID: 34381732)
Nat Immunol. 2015 Apr;16(4):343-53. (PMID: 25789684)
J Virol. 2013 Nov;87(21):11401-15. (PMID: 23966390)
EMBO Mol Med. 2024 Nov;16(11):3005-3025. (PMID: 39322862)
Nat Rev Immunol. 2006 Nov;6(11):823-35. (PMID: 17063184)
Annu Rev Immunol. 2014;32:461-88. (PMID: 24655297)
Immunology. 2004 Jul;112(3):369-77. (PMID: 15196204)
Nat Rev Cancer. 2022 Jul;22(7):397-413. (PMID: 35355007)
Nat Med. 2023 Sep;29(9):2278-2285. (PMID: 37592104)
Nat Immunol. 2010 May;11(5):373-84. (PMID: 20404851)
Eur J Immunol. 2010 Mar;40(3):624-7. (PMID: 20201016)
Curr Opin Virol. 2015 Jun;12:7-14. (PMID: 25644461)
Nat Immunol. 2009 Feb;10(2):203-13. (PMID: 19122653)
Immunity. 2024 Apr 9;57(4):632-648. (PMID: 38599163)
Nat Immunol. 2016 Dec;17(12):1459-1466. (PMID: 27695003)
Immunity. 2010 May 28;32(5):692-702. (PMID: 20434372)
Nat Immunol. 2021 Apr;22(4):423-433. (PMID: 33767427)
Signal Transduct Target Ther. 2025 Jul 11;10(1):216. (PMID: 40640149)
J Immunol. 2017 Mar 15;198(6):2260-2268. (PMID: 28159898)
PLoS One. 2010 Oct 18;5(10):e13418. (PMID: 20976143)
Cancer Discov. 2020 Jan;10(1):26-39. (PMID: 31852718)
Nat Rev Immunol. 2016 Jul;16(7):433-48. (PMID: 27291962)
Am J Transplant. 2011 Feb;11(2):203-14. (PMID: 21219575)
J Immunol. 2006 Nov 15;177(10):6573-8. (PMID: 17082566)
J Exp Med. 2002 Mar 4;195(5):F19-23. (PMID: 11877490)
Immunity. 2011 May 27;34(5):637-50. (PMID: 21616434)
Cells. 2020 Mar 13;9(3):. (PMID: 32183240)
Immunity. 2020 Jul 14;53(1):115-126.e5. (PMID: 32640258)
J Exp Med. 2003 Feb 17;197(4):403-11. (PMID: 12591899)
Nat Rev Immunol. 2012 Dec;12(12):813-20. (PMID: 23175229)
Cell Rep. 2021 Nov 23;37(8):110000. (PMID: 34818548)
Nature. 2014 Oct 16;514(7522):372-375. (PMID: 25119032)
Pharmaceutics. 2022 Feb 16;14(2):. (PMID: 35214155)
J Biol Chem. 1999 May 21;274(21):14560-7. (PMID: 10329646)
Front Immunol. 2021 Aug 19;12:706583. (PMID: 34489958)
J Clin Invest. 2023 May 1;133(9):. (PMID: 36927693)
Nature. 2009 Mar 26;458(7237):514-8. (PMID: 19158675)
Cell. 2006 Feb 24;124(4):783-801. (PMID: 16497588)
Nat Immunol. 2011 Feb;12(2):121-8. (PMID: 21245903)
Nature. 2021 Mar;591(7849):300-305. (PMID: 33505023)
Nat Immunol. 2005 Oct;6(10):981-8. (PMID: 16127453)
Hum Vaccin Immunother. 2024 Dec 31;20(1):2297453. (PMID: 38155525)
Cell Mol Life Sci. 2011 Jul;68(14):2357-70. (PMID: 21560072)
Front Microbiol. 2023 Jan 27;14:1033448. (PMID: 36778871)
Mol Cells. 2025 Aug;48(8):100239. (PMID: 40527410)
Signal Transduct Target Ther. 2025 Jul 18;10(1):225. (PMID: 40675966)
Scand J Immunol. 2009 Sep;70(3):245-55. (PMID: 19703014)
J Immunol. 2006 Feb 1;176(3):1348-54. (PMID: 16424161)
Clin Rheumatol. 2024 Nov;43(11):3537-3549. (PMID: 39356380)
Sci Transl Med. 2020 Jun 24;12(549):. (PMID: 32581136)
J Immunol. 2009 Jul 15;183(2):787-91. (PMID: 19570822)
Signal Transduct Target Ther. 2021 Aug 4;6(1):291. (PMID: 34344870)
Immunity. 2010 Oct 29;33(4):492-503. (PMID: 21029960)
Biomed J. 2024 Feb;47(1):100635. (PMID: 37574163)
Cell Mol Immunol. 2021 Mar;18(3):539-555. (PMID: 33462384)
Cell. 2024 Dec 26;187(26):7414-7432.e26. (PMID: 39476839)
J Immunol. 2004 May 15;172(10):6065-73. (PMID: 15128790)
Nat Commun. 2024 Feb 1;15(1):308. (PMID: 38302456)
Front Immunol. 2022 Sep 02;13:979116. (PMID: 36119037)
Front Immunol. 2018 Feb 13;9:225. (PMID: 29487599)
Nat Biomed Eng. 2018 Aug;2(8):578-588. (PMID: 31015631)
BMC Evol Biol. 2011 Dec 20;11:368. (PMID: 22185391)
Nat Med. 2017 May;23(5):556-567. (PMID: 28394331)
Cell Rep Med. 2024 May 21;5(5):101560. (PMID: 38729159)
Immunity. 2012 Aug 24;37(2):235-48. (PMID: 22841161)
Nat Rev Immunol. 2017 Mar;17(3):208-214. (PMID: 28163301)
Am J Nephrol. 2014;40(4):325-44. (PMID: 25341693)
Nat Rev Immunol. 2008 Dec;8(12):911-22. (PMID: 18989317)
Immunity. 2024 Apr 9;57(4):649-673. (PMID: 38599164)
Contributed Indexing:
Keywords: T cell; pathology; pattern recognition receptors
Substance Nomenclature:
0 (Receptors, Pattern Recognition)
Entry Date(s):
Date Created: 20251220 Date Completed: 20260129 Latest Revision: 20260204
Update Code:
20260204
PubMed Central ID:
PMC12862620
DOI:
10.3724/abbs.2025227
PMID:
41420400
Database:
MEDLINE
*Further Information*
*The immune system orchestrates a delicate balance between robust defense against pathogens and restraint to prevent tissue damage, with T cells serving as central mediators of adaptive immunity. The canonical pathway for T-cell activation hinges on the precise recognition of peptide antigens presented by major histocompatibility complex (MHC) molecules via the T-cell receptor (TCR), which is complemented by essential co-stimulatory signals. However, this model alone cannot fully explain the nuanced contextualization of immune responses, particularly how T cells integrate signals related to the nature of the threat. Pattern recognition receptors (PRRs), which are traditionally studied in innate immune cells, are recognized as critical regulators of T cell function, challenging the conventional dichotomy between innate and adaptive immunity. T cell-intrinsic PRR signaling integrates endogenous danger signals and microbes to modulate critical processes, including cytokine production, proliferation, and polarization, thereby shaping immune responses and disease outcomes in contexts ranging from viral infections to chronic inflammation and cancer. However, the molecular mechanisms underlying PRR-mediated T cell regulation and their contributions to immune homeostasis or pathology remain incompletely understood. This study investigates the role of T cell-intrinsic PRR signaling in shaping immune responses and its implications for disease. By elucidating key signaling pathways and their impact on T cell function, we aim to offer novel insights into the complex regulation of T cell-mediated immunity and uncover an underappreciated paradigm for immune-related disorders, providing new insights into the pathogenesis of inflammatory and neoplastic diseases.*